Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
24.04
+0.34 (1.43%)
At close: May 29, 2025, 4:00 PM
24.47
+0.43 (1.79%)
After-hours: May 29, 2025, 5:18 PM EDT
Janux Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 73.74 | 430.61 | 19.21 | 51.43 | 35.58 | 7.81 | Upgrade
|
| Short-Term Investments | 940.4 | 594.57 | 324.82 | 275.59 | 339.38 | - | Upgrade
|
| Cash & Short-Term Investments | 1,014 | 1,025 | 344.03 | 327.02 | 374.97 | 7.81 | Upgrade
|
| Cash Growth | 55.60% | 197.99% | 5.20% | -12.79% | 4699.24% | 1087.39% | Upgrade
|
| Accounts Receivable | - | - | - | - | - | 8 | Upgrade
|
| Other Receivables | 5.59 | 5.38 | 2.16 | 0.7 | 0.2 | - | Upgrade
|
| Receivables | 5.59 | 5.38 | 2.16 | 0.7 | 0.2 | 8 | Upgrade
|
| Prepaid Expenses | 3.61 | 3.11 | 3.05 | 4.72 | 1.85 | 0.25 | Upgrade
|
| Total Current Assets | 1,023 | 1,034 | 349.24 | 332.44 | 377.02 | 16.06 | Upgrade
|
| Property, Plant & Equipment | 23.83 | 24.15 | 27.84 | 29.37 | 1.6 | 0.16 | Upgrade
|
| Other Long-Term Assets | 3.61 | 3.7 | 3.33 | 2.21 | 1.21 | - | Upgrade
|
| Total Assets | 1,051 | 1,062 | 380.41 | 364.01 | 379.82 | 16.22 | Upgrade
|
| Accounts Payable | 2.35 | 4.03 | 2.42 | 2.16 | 2.46 | 0.43 | Upgrade
|
| Accrued Expenses | 13.34 | 11.68 | 7.39 | 8.18 | 3.78 | 0.75 | Upgrade
|
| Current Portion of Leases | 1.81 | 1.75 | 1.52 | 0.76 | 0.19 | - | Upgrade
|
| Current Unearned Revenue | - | - | 1.71 | 5.41 | 5.16 | 1.95 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 1.2 | 0.05 | Upgrade
|
| Total Current Liabilities | 17.5 | 17.46 | 13.03 | 16.51 | 12.8 | 3.18 | Upgrade
|
| Long-Term Leases | 20.8 | 21.28 | 23.03 | 24.54 | - | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 2.22 | 0.7 | 6.05 | Upgrade
|
| Total Liabilities | 38.3 | 38.74 | 36.06 | 43.27 | 13.5 | 9.23 | Upgrade
|
| Common Stock | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,270 | 1,258 | 512.4 | 432.7 | 413.97 | 0.1 | Upgrade
|
| Retained Earnings | -261.27 | -237.76 | -168.76 | -110.47 | -47.41 | -14.74 | Upgrade
|
| Comprehensive Income & Other | 3.76 | 2.16 | 0.67 | -1.54 | -0.27 | - | Upgrade
|
| Total Common Equity | 1,012 | 1,023 | 344.35 | 320.74 | 366.33 | -14.64 | Upgrade
|
| Shareholders' Equity | 1,012 | 1,023 | 344.35 | 320.74 | 366.33 | 6.99 | Upgrade
|
| Total Liabilities & Equity | 1,051 | 1,062 | 380.41 | 364.01 | 379.82 | 16.22 | Upgrade
|
| Total Debt | 22.61 | 23.03 | 24.54 | 25.31 | 0.19 | - | Upgrade
|
| Net Cash (Debt) | 991.53 | 1,002 | 319.49 | 301.71 | 374.77 | 7.81 | Upgrade
|
| Net Cash Growth | 57.99% | 213.68% | 5.89% | -19.50% | 4696.76% | - | Upgrade
|
| Net Cash Per Share | 17.41 | 18.64 | 7.26 | 7.28 | 15.93 | 8.54 | Upgrade
|
| Filing Date Shares Outstanding | 59.18 | 59.11 | 51.65 | 41.76 | 41.24 | 1.26 | Upgrade
|
| Total Common Shares Outstanding | 59.17 | 59.06 | 46.24 | 41.62 | 41.24 | 1.26 | Upgrade
|
| Working Capital | 1,006 | 1,016 | 336.21 | 315.93 | 364.22 | 12.88 | Upgrade
|
| Book Value Per Share | 17.11 | 17.32 | 7.45 | 7.71 | 8.88 | -11.64 | Upgrade
|
| Tangible Book Value | 1,012 | 1,023 | 344.35 | 320.74 | 366.33 | -14.64 | Upgrade
|
| Tangible Book Value Per Share | 17.11 | 17.32 | 7.45 | 7.71 | 8.88 | -11.64 | Upgrade
|
| Machinery | 10.18 | 9.81 | 9.87 | 7.91 | 1.4 | 0.18 | Upgrade
|
| Construction In Progress | - | - | - | - | 0.14 | - | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.